Veeva Vault CDMS Selected for Enterprise-wide Deployment
Veeva Systems announced that a top 20 pharmaceutical company has selected Veeva Vault Clinical Data Management System (CDMS) as their global standard for EDC, coding, data cleaning, and reporting.
“This is a landmark announcement for the clinical data management market,” said Henry Levy, general manager, Veeva Vault CDMS. “Veeva Vault CDMS was selected because the company wanted a modern cloud solution on a world-class platform from a partner they could trust.”
Vault CDMS provides a suite of clinical data management applications that combines coding, EDC, data cleaning, and reporting all on a single cloud platform. Companies can now manage study build through execution in an integrated way. With a complete and concurrent view of their data, clinical development teams can make better decisions.
As part of Vault CDMS, Veeva Vault EDC provides an intuitive interface for capturing clinical trial data. Designed for flexibility, Vault EDC allows customers to run complex multi-arm adaptive trials and make mid-study amendments without downtime or migrations.
“Our goal is to become the market leader in the clinical data management market over time through innovation and product excellence,” added Levy. “We are honored to partner with this important customer and look forward to delivering customer success for many years.”
For more on Veeva Vault CDMS, visit: veeva.com/CDMS
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
